Eli Lilly & Co.'s Inc.'s stock soared 13% in premarket trade Thursday, after the drug maker reported positive results from a late-stage trial of an oral GLP-1 treatment for Type 2 diabetes.
The company $(LLY)$ said orforglipron showed statistically significant results and a safety profile that was consistent with injectable GLP-1 medicines in the Phase 3 trial. The once-daily treatment reduced weight by an average of 16 lbs at the highest dose in a secondary endpoint.
The drug is the first oral small-molecule GLP-receptor agonist to successfully complete a Phase 3 trial, said Lilly in a statement.
"We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control and weight loss, and we look forward to additional data readouts later this year," said Lilly CEO David A. Ricks in prepared remarks.
(This is a breaking news story. Check back for updates)
-Ciara Linnane
For more from MarketWatch: http://www.marketwatch.com/newsviewer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 17, 2025 07:15 ET (11:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.